Paid Clinical Trials Fairbanks
Discover 16 paid clinical trials in Fairbanks, Alaska. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Observational StudyEfficacy-Implementation Study for PC CARES in Rural Alaska
Sponsor:
University of Michigan
Location:
Code:
NCT06658808
Conditions
Suicide Prevention
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Accepted
Interventions
Promoting Community Conversations About Research to End Suicide
QungasvikQungasvik (Toolbox): Prevention of Alcohol/Suicide Risk in Alaska Native Youth
Sponsor:
University of Alaska Fairbanks
Location:
Code:
NCT05400135
Conditions
Suicide
Alcohol Use Disorder
Eligibility Criteria
Sex: All
Age: 12 - 21
Healthy Volunteers: Accepted
Interventions
Qungasvik (Tools for Life)
BiomarkersUsing Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT04462406
Conditions
Advanced Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Melanoma of Unknown Primary
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ipilimumab
Nivolumab
Patient Observation
Pembrolizumab
Observational StudyEvaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT06002828
Conditions
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Quality-of-Life Assessment
Questionnaire Administration
Regional RadiotherapyRegional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Sponsor:
Canadian Cancer Trials Group
Location:
Code:
NCT03488693
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 35+
Healthy Volunteers: Not accepted
Interventions
Radiation
No Radiation
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Pembrolizumab & OlaparibTesting the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04548752
Conditions
Metastatic Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy Procedure
Biospecimen Collection
Computed Tomography
Magnetic Resonance Imaging
Olaparib
Green TeaTo Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT04597359
Conditions
Prostate Carcinoma
Eligibility Criteria
Sex: All
Age: 21+
Healthy Volunteers: Not accepted
Interventions
Placebo Administration
Quality-of-Life Assessment
Questionnaire Administration
Sinecatechins
Venetoclax & ObinutuzumabTesting Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04269902
Conditions
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Computed Tomography
Obinutuzumab
Encorafenib & BinimetinibA Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT04511013
Conditions
Acral Lentiginous Melanoma
Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Cutaneous Melanoma
Metastatic Malignant Neoplasm in the Brain
Metastatic Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Binimetinib
Encorafenib
Ipilimumab
Nivolumab
OlaparibAPOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04858334
Conditions
Pancreatic Acinar Cell Carcinoma
Pancreatic Adenosquamous Carcinoma
Pancreatic Squamous Cell Carcinoma
Resectable Pancreatic Acinar Cell Carcinoma
Resectable Pancreatic Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Magnetic Resonance Imaging
Olaparib
Placebo Administration